Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy
and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment
of acute schizophrenic patients. The eligible patient will be assigned to study treatment
with Quetiapine XR on Day 1.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation
was changed to XR after consultation with FDA.